Approved, Compounded and Other GLP-1 Formulations: Read the Product Before Signing

Before accepting a GLP-1 enrollment agreement, finish this sentence: “The product I am being evaluated for is…” An ingredient name alone may not finish it. The consulted documentation describes branded tablets, injection pens, compounded injections, vitamin-containing formulations, combination products and programs called microdosing. Those descriptions belong beside the payment and cancellation terms—not on a separate marketing page that disappears once checkout begins.

This guide examines public documentation from CoreAge Rx, Ro, Enhance.MD, Sesame, Walgreens and Found, consulted October 19, 2026. Its purpose is contractual clarity, not a treatment comparison. FDA approval belongs to a specific product, not the platform arranging care. Likewise, clear commercial terms do not prove clinical equivalence, and a prescription evaluation does not necessarily promise the product a customer preferred. The practical goal is to identify exactly what is offered, who decides whether to prescribe it and when financial obligations become difficult to reverse.

At a glance

FDA distinction: Compounded preparations are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality. Nonapproval alone does not establish clinical inequivalence.
Sources: [1]
An ingredient name may conceal formulation differences: CoreAge Rx says its compounded tirzepatide is typically formulated with B-12; a formulation without B-12 can be discussed during intake with the provider.
Sources: [13]
A combination is a separate product description: Enhance.MD markets GLP-1 Elite as an injection combining semaglutide and tirzepatide, distinct from its Core semaglutide and Advanced compounded tirzepatide offerings.
Sources: [31] [6] [23]
Presentation affects offer terms: Walgreens describes the Zepbound KwikPen self-pay offer as one pen for 28 days, with dose-specific prices, refill-timing conditions and a limit on discounted fills.
Sources: [19]
A preferred product may not control refunds: Found says disqualification from a particular medication does not qualify for a membership refund if other treatment options remain available.
Sources: [21]

Start with the product description, not the program name

Program labels organize a website; they do not necessarily identify the prescription. Enhance.MD calls its semaglutide injection GLP-1 Core, its compounded tirzepatide offering GLP-1 Advanced and its semaglutide-plus-tirzepatide injection GLP-1 Elite. CoreAge Rx separately advertises Semaglutide Microdosing Therapy and Tirzepatide Microdosing Therapy. These are useful catalog identifiers, but the agreement should also identify the actual formulation, route and presentation being considered. A tier name or metabolic-support slogan cannot substitute for that information.

The distinction also prevents unrelated items from being swept into the same category. CoreAge Rx explicitly calls GLP-1 Support a dietary supplement, not a prescription medication. Enhance.MD displays NAD+ injections and sublingual wafers alongside GLP-1 offerings; those are separate complementary products. Ask which selected item the checkout price covers and whether any adjacent product is optional. The broader checklist in what to ask for in a written GLP-1 quote can help preserve that answer before payment.

Product language worth preserving before checkout
Documented example	What the description establishes	What still needs confirmation
CoreAge Rx compounded tirzepatide, typically with B-12	The usual formulation includes another ingredient	The prescribed formulation and whether a requested alternative is approved
Ro Wegovy pill versus Wegovy pen	The catalog distinguishes oral and injectable presentations	The selected product, applicable price and pharmacy channel
Enhance.MD GLP-1 Elite	The advertised injection combines semaglutide and tirzepatide	The exact prescription and formulation-specific documentation
Sesame Zepbound pens, KwikPens and vials	The page lists three different presentations	Which presentation the prescription and cash offer cover
CoreAge Rx GLP-1 Support	The seller identifies it as a dietary supplement	Whether it is a separate optional purchase

Sources: [6] [23] [31] [15] [16] [8] [11]

Keep FDA approval attached to the specific product

FDA explains that compounded preparations are not approved and do not undergo its premarket review for safety, effectiveness and quality. FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. That recommendation should remain part of the discussion; it is not a blanket legal conclusion about every transaction. Equally, nonapproval by itself neither establishes clinical inequivalence nor validates or condemns a particular provider.

Provider disclosures sometimes make this boundary explicit. CoreAge Rx distinguishes approved semaglutide products from compounded formulations. Enhance.MD’s Core page says its compounded formulation is not FDA approved and describes prescription access for patients with demonstrated clinical need. Found also discloses that compounded medications are not FDA approved or evaluated by FDA for safety or efficacy. Preserve those disclosures with the product description rather than replacing them with the shorthand “FDA-approved ingredient.” That shorthand does not describe the regulatory status of the dispensed preparation.

Sources: [1] [18] [6] [21]

Route, presentation and added ingredients are not interchangeable details

Ro identifies its Wegovy pill as oral semaglutide and separately describes the Wegovy pen. Sesame lists Zepbound single-dose pens, multidose KwikPens and single-dose glass vials requiring a separate needle and syringe. These distinctions matter when matching a prescription to an offer or fulfillment arrangement. Do not assume that a price, pharmacy option or inclusion attached to one presentation also applies to another simply because both descriptions contain the same ingredient or brand name.

CoreAge Rx’s B-12 disclosure illustrates another layer: an ingredient label may not list the whole formulation. FDA also states that semaglutide sodium and semaglutide acetate are different active ingredients from those used in approved drugs. The consulted documentation does not establish that any reviewed provider uses those salts, so no such attribution is warranted. Ask for exact ingredients rather than drawing conclusions from omissions. Nor should a combination, vitamin blend or changed route inherit an equivalence claim from a different product.

Sources: [14] [24] [10] [13] [1]

Match the price to the exact item and billing period

Walgreens provides a concrete example of why presentation belongs in the financial record. Its Wegovy tablet self-pay offer lists $149 monthly for the 1.5 mg presentation, $199 for 4 mg and $299 for 9 mg or 25 mg, with one bottle of 30 tablets covering 30 days. Its injection offer instead describes 28-day fills: eligible self-paying patients new to Wegovy injections pay $199 for each of the first two selected fills, limited to 0.25 mg and 0.5 mg, through December 31, 2026; subsequent fills are $349 monthly. Visits cost extra.

Ro separates medication from membership. Its membership advertises $39 for the first month, then $149 monthly on a monthly plan, or an equivalent amount as low as $74 monthly with annual prepayment. CoreAge Rx advertises compounded semaglutide from $79 monthly and tirzepatide from $129 monthly, with supplies and free shipping, but the consulted pages do not establish the quantities or conditions securing those minimums. As the billing-commitment guide explains, a monthly display is not enough to identify either the collection schedule or commitment.

Sources: [19] [4] [20]

Identify who can prescribe and which pharmacy can fulfill

A platform’s product catalog is not a guaranteed prescription. Enhance.MD says it supplies administrative support, does not provide medical or pharmacy services and does not control clinical decisions; payment does not guarantee prescribing or dispensing. CoreAge Rx similarly assigns evaluation, treatment planning and prescribing to independent professional entities rather than its administrative platform. Sesame’s terms explicitly leave prescribing to the provider’s discretion and medical necessity. These allocations should inform whom you contact when a product request changes during evaluation.

Pharmacy choice also needs a product-specific answer. CoreAge Rx’s FAQ requires its affiliated network, while its terms allow a requested outside pharmacy before order completion. Enhance.MD allows a chosen pharmacy but says medication is billed separately in that arrangement; its FAQ and terms list different partners. Found permits branded prescriptions through a chosen pharmacy or, when eligible, NovoCare or LillyDirect, describing the latter channels as cash-pay only. Use the responsibility-mapping guide to separate platform administration, clinical decisions and pharmacy fulfillment.

Sources: [11] [20] [7] [13] [22] [12] [25] [21]

Resolve product changes before refund rights narrow

The decisive question may be whether enrollment purchases evaluation for one named product or access to a broader set of options. Found says being ruled out for a preferred medication does not qualify for a membership refund when another treatment remains available. Enhance.MD’s Core guarantee instead promises a full initial-payment refund if onboarding determines the patient is ineligible for its formulation. Neither statement should be stretched into a general results guarantee or an unconditional right to reject any later recommendation without financial consequences.

CoreAge Rx shows why the timing deserves written clarification. Its FAQ promises an automatic 100% refund if prescribing is not approved, but its refund policy retains an applicable $50–$100 consultation fee. The policy also makes prescription sales final after both approval and transmission to the pharmacy, even before shipment, and imposes a 30-calendar-day nonrefundability boundary subject to applicable law. Ask about these conflicts before paying; refund guarantees and their exclusions addresses why canceling future renewals does not automatically reverse an existing order.

Sources: [21] [6] [13] [5]

Read microdosing and quality language without importing outcomes

Microdosing is a program description, not evidence that a product has approval for a particular purpose. Found’s microdosing page says its compounded GLP-1 products are not approved to treat any specific condition and require clinical evaluation. CoreAge Rx markets separate microdosing therapies, while Enhance.MD describes tirzepatide microdosing deliveries every 12 weeks, unlike its main programs’ four-week delivery schedule. Those documented differences identify offerings and logistics; they do not establish longevity benefits, greater effectiveness or better tolerability.

Quality claims need similarly careful attribution. Found says its compounded semaglutide receives third-party potency, purity and sterility testing, but the consulted documentation does not name the testing laboratory or provide certificates. Such statements should not be rewritten as independent verification. The clinical trials included in the consulted clinical context were not studies of these providers’ compounded preparations, microdoses, blends or combination products. Their outcomes cannot fill gaps in product-specific documentation or establish what an individual purchaser should expect.

Sources: [9] [15] [16] [27] [6] [17] [2] [3]

Carry the product description through delivery and renewal

The description should survive beyond checkout: prescription, pharmacy confirmation and delivery information should identify the product actually being fulfilled. CoreAge Rx estimates arrival approximately two to three business days after pharmacy shipment, separately from review and preparation. Ro says cash-pay prescriptions sent to its or partner pharmacies ship within a week once prescribed; that is dispatch, not arrival. Neither statement establishes product-specific temperature handling. FDA advises not using injectable GLP-1 medication that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy.

Renewal terms deserve the same precision as the initial order. Sesame’s program page allows cancellation before the next cycle, but its general terms require email or telephone cancellation at least 48 hours before renewal processing. Walgreens says approved Bridge fills will be set up for next-month autofill; its no-subscription visit model does not erase that separate pharmacy process. Confirm which product, service and order will renew, and obtain the applicable cancellation procedure rather than assuming one cancellation stops every component.

Sources: [5] [26] [1] [28] [7] [30] [19]

Questions & answers

Does CoreAge Rx’s tirzepatide description mean every prescription includes B-12?

No. Its FAQ says compounded tirzepatide is typically formulated with B-12 and invites patients to raise a preference for a formulation without it during intake. That is an opportunity for discussion, not a guaranteed alternative. Confirm the formulation the clinician actually prescribes before treating the checkout description as final.

Sources: [13]

Does Ro membership pay for whichever GLP-1 product is prescribed?

No. Ro explicitly excludes medication cost from its membership fee. Its insurance coordination currently applies to Wegovy pen, Zepbound autoinjector pen and Ozempic, while some other catalog items are cash-pay only. Ask for separate membership and medication charges and confirm that the selected presentation qualifies for the intended payment channel.

Sources: [4] [26]

Is Enhance.MD Elite simply another name for its tirzepatide product?

No. Enhance.MD describes Advanced as compounded tirzepatide and Elite as an injectable formulation combining semaglutide and tirzepatide. Those are different descriptions. The Elite marketing language does not establish superiority or equivalence to another product. Request formulation-specific documentation rather than relying on the tier name.

Sources: [23] [31]

Can I apply Sesame’s Zepbound vial price to a KwikPen?

Do not assume so. Sesame publishes separate LillyDirect cash-price schedules for vials and KwikPens, and some KwikPen amounts also differ between its general and product-specific pages. Confirm the presentation, current channel price and separate subscription charge before enrollment. A shared brand name does not resolve those pricing differences.

Sources: [10] [28]

What conditions accompany Walgreens’ Zepbound KwikPen self-pay offer?

The documented offer runs through December 31, 2026: $299 for the 2.5 mg presentation, $399 for 5 mg and $449 for the listed higher presentations, per 28-day supply of one KwikPen. Continuing eligibility requires refill purchase within 45 days of receiving the prior fill. It operates outside insurance, allows up to 11 fills per calendar year and excludes visit charges.

Sources: [19]

Does Found’s “with insurance” compounded price mean insurance covers the preparation?

No. Found says that pricing reflects insurance coverage for clinical care; its consent makes the patient responsible for compounded medication charges and prohibits submitting those amounts to insurance. Copays, coinsurance and deductibles can still apply. The distinction is between components of care, not proof that the compounded drug itself is an insured benefit.

Sources: [21] [29]

Our assessment

A useful enrollment record names the product precisely and connects it to the prescribing decision, pharmacy channel, payment schedule and refund boundary. The consulted providers disclose meaningful differences, but several also publish conflicting commercial terms or incomplete formulation details. Those gaps justify questions, not assumptions that a service is unavailable or a product is equivalent or inequivalent. Before paying, preserve the applicable description and obtain written clarification of material conflicts. Contract clarity can make a transaction more understandable; it cannot substitute for product-specific clinical evidence or a treating clinician’s judgment.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Approved, Compounded and Other GLP-1 Formulations: Read the Product Before Signing

At a glance

01Start with the product description, not the program name

02Keep FDA approval attached to the specific product

03Route, presentation and added ingredients are not interchangeable details

04Match the price to the exact item and billing period

05Identify who can prescribe and which pharmacy can fulfill

06Resolve product changes before refund rights narrow

07Read microdosing and quality language without importing outcomes

08Carry the product description through delivery and renewal